Product Description
Grit BioTech is developing an Autologous Tumor-Infiltrating Lymphocyte for the treatment of solid tumors. (Sourced from: https://clinicaltrials.gov/study/NCT06453057)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Grit Biotechnology
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for GT-307](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
GRIT-CD-CHN-307-005 | N/A |
Recruiting |
Oncology Solid Tumor Unspecified |
2027-06-06 |
|
GRIT-CD-CHN-307-002 | N/A |
Recruiting |
Oncology Solid Tumor Unspecified |
2027-04-18 |